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Abstract 
Introduction: Oral squamous cell carcinoma (OSCC) the sixth leading cancer worldwide ranks as the 
most common cancer in males, and the third most common in females in Pakistan. It is influenced by risk 
factors which are widely consumed in our population. The epidermal growth factor receptor (EGFR) is a 
tyrosine kinase receptor that is imperative for cell signalling, growth and differentiation. It is mutated and 
overexpressed in a variety of cancers, while in OSCC it has been linked to poor patient survival; 
premalignant to malignant transformation and recurrence. This study investigates the use of EGFR as a 
prognostic factor for OSCC. 
Materials and Methods: Premalignant (n=29) and OSCC (n=100) formalin-fixed paraffin-embedded 
tissues were retrieved from the surgical archives of Aga Khan University Hospital (AKUH). 
Immunohistochemistry for EGFR overexpression was performed using monoclonal antibody on both 
groups. EGFR expression was correlated with habits of risk factor consumption, clinicopathologic 
features and 5-year survival and recurrence.  
Results: 15/29 premalignant and 67/100 OSCC patients had overexpressed EGFR. The upper/lower lip 
had the highest EGFR positivity among all premalignant sites of lesion (p=0.041). In OSCC patients, those 
who had EGFR overexpression had worse 5-year survival (univariate: p=0.048, multivariate: p=0.056) and 
higher chances of recurrence (univariate: p=0.01, multivariate: p=0.004) as compared to EGFR negative 
patients. 
Conclusion: EGFR is a viable candidate for an OSCC prognostic marker since its overexpression leads 
to poor survival and markedly increases the chances of recurrence. 
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Introduction 
Oral cancer makes up 3-4% of all cancers 
worldwide and is currently the sixth most common 
cancer. The oral squamous cell carcinoma (OSCC) is 
the most frequent type and comprises 90% of all 
malignancies of the oral cavity [1]. Globally in the 
year 2012, the highest rates for lip and oral cavity 
cancers were found in South-Central Asia, Central 
and Eastern Europe and Melanesia; whereas Western 
Africa and Eastern Asia boasted the lowest 
incidences. Cancers of the oral cavity and pharynx 
together made up 52900 new cases and were 
responsible for 292000 deaths [2]. The survival of 
OSCC patients is bleak with a 5-year survival rate of 
40-50% [3] which is in part due to patients presenting 
with advanced disease at the time of diagnosis and 
partly due to inadequate treatment and disease 
management strategies. Moreover, 50% of patients are 
seen to develop recurrence within the first 2 years of 
treatment leading to a worse prognosis [4]. It was 
reported by Camisasca et al. that 5 year survival rates 
for OSCC patient with and without recurrence were 








Pakistan is considered one of the high-risk 
regions of the world for head and neck cancers [6]. 
GLOBOCAN figures for 2012 reveal that lip and oral 
cavity cancers are the second-most common cancer in 
Pakistan with 4,046 deaths in males and 3,220 deaths 
in females attributed to lip and oral cavity cancers [7]. 
Lip and oral cavity cancers ranked as the most 
common type of cancer for Pakistani males and the 
third most common type for Pakistani females, being 
the second most common cancer overall [8, 9]. The 
world’s highest incidence for oral cavity cancer has 
been reported in Karachi [10, 11] and this is believed 
to be due to the habitual and widespread use of 
various OSCC risk factors. An increasing incidence of 
oral cancer among the youth has also been noted with 
a 60% increase in the number of patients below the 
age of 40 over the past 30 years [12]. 
Several risk factors have been identified as key 
players in the development and progression of OSCC 
such as tobacco smoking [7], smokeless tobacco [13] 
alcohol [14], betel quid [15] and areca nut chewing 
[16] and HPV infection [17]. Additionally, an equally 
common use of risk factors has been observed in both 
genders in Pakistan. This may be a reason for the 
equally high prevalence of oral cancer in both sexes 
which is a statistic not observed in other regions of the 
world. Moreover, alcohol has not been implicated as a 
significant risk factor in the population of Karachi, 
due to lower consumption as compared to the west. 
Whereas tobacco, areca nut and betel quid in the 
cultural forms of paan, supari, gutka, niswar and 
chalia is much more common [18]. A recent survey 
revealed that 36% of males and 44% of females 
consumed paan alone or in conjunction with tobacco 
and this correlated with the high prevalence of oral 
cavity cancers [12]. 
The exact cause of OSCC is unknown; however, 
many genetic mutations are thought to be involved in 
its development and progression. Prominent genes 
believed to have a role in the carcinogensis of OSCC 
are TP53, NOTCH 1, EGFR, CDKN2A, STAT3, Cyclin 
D1 and Rb [19]. The epidermal growth factor 
regulator (EGFR) is a transmembrane growth factor 
receptor with a molecular weight of 170 kDaltons 
which binds with many ligands including epidermal 
growth factor, amphiregulin, betacellulin, TGF- α and 
others. Binding of any of these ligands to the receptor 
induces conformational changes resulting in intrinsic 
tyrosine kinase activity which activates multiple 
signalling pathways that regulate cell proliferation, 
differentiation, motility and survival [20]. 
Oral premalignant lesions precede oral carcino-
mas in about 67% of cases, with leukoplakia being the 
most common lesion. Statistically speaking, 1%-18% 
of these premalignant lesions will undergo 
transformation into malignancy [21]. EGFR has been 
associated in premalignant lesions in two ways: 
Firstly, gene amplification of EGFR was observed to 
help transformation of premalignant lesions into 
malignant oral conditions by Benchekroun et al. [22]. 
Secondly, Poh et al. found that increased EGFR gene 
gain of any level (high or low) had a strong 
association with progression into malignancy and 
aggressive clinical behaviour [23]. 
The impact of EGFR on survival and pattern of 
relapse was tested in a correlative study of HNSCC 
patients and it was seen that patients with 
overexpressed EGFR had significantly lower overall 
survival and disease free survival rates. It was 
concluded that EGFR was a significant independent 
determinant of survival and a strong predictor for 
locoregional relapse [24]. Various other cancers have 
also been found to harbour EGFR mutations and 
overexpression such as glioblastoma multiforme [25], 
lung cancer [26], head and neck squamous cell carcin-
oma [27], breast [28], colorectal [29] and oesophageal 
cancers [30] leading to a worse patient prognosis. 
A study utilized next-generation sequencing and 
identified EGFR as one of the most commonly 
mutated cancer-related gene in OSCC [31] and it is 
also considered a major player in oral carcinogenesis 
[32] as it was found to harbour genetic alterations as a 
result of repeated exposure to risk factors [19]. 
According to Gupta et al., EGFR overexpression lead 
to lower overall survival, overall response and quality 
of life in patients with locally advanced OSCC who 
had been treated with chemoradiation [33]. Furtherm-
ore, a meta-analysis of thirty-seven studies was 
conducted by Keren et al. to analyse the prognostic 
value of EGFR in HNSCC and it revealed that EGFR 
overexpression to lead to lower survival and disease- 
free survival for oropharyngeal carcinoma [34].  
To the best of our knowledge; no studies 
concerning the role of EGFR in OSCC in the Pakistani 
population have been performed before. The evidence 
for the impact of EGFR on survival and recurrence 
deserves to be explored in the Pakistani population as 
it suffers from a record high prevalence of OSCC and 
patients encounter inadequate diagnostic and 
treatment measures. EGFR has the potential to 
become a target for therapeutic measures in the form 
of monoclonal antibodies or tyrosine kinase inhibitors 
as has been the case for breast [28], colorectal and lung 
cancer [35]. As a result, improvement in patient 
prognosis and overall survival may be seen. Our 
objective for this study was to determine EGFR 
expression in premalignant and OSCC patients of 
Pakistan and explore its impact on 5-year survival and 




recurrence in OSCC patients.  
Materials and Methods  
Study Population 
The study was a retrospective series in which 
patients who had been diagnosed and treated at Aga 
Khan University Hospital (AKUH), Karachi, Pakistan 
from the year 1991 to 2004 were included, amounting 
to a total of 29 premalignant and 100 OSCC patients. 
All patients provided written informed consent for 
their participation. Ethical approval was obtained 
prior to the start from the Ethical Review Committee 
of AKUH. Patients who did not have complete 
medical records, 5-year follow up data, had inadequ-
ate samples or those who had undergone treatment 
beyond AKUH were excluded. For each case, the 
following information was obtained: age, gender, site 
of primary lesion, type of lesion, histological 
differentiation, AJCC and TNM stages, habit history 
(meaning use of any risk factors such as tobacco, betel 
quid or areca nut) and surgical margin status. 
 EGFR Immunohistochemical Assay 
Formalin-fixed paraffin embedded blocks of 
selected patients were retrieved from the histo-
pathology laboratory of AKUH. 4µm thick sections of 
each tissue block were sliced onto precoated glass 
slides and heated in an oven at 55ºC for an hour. 
Sections were deparaffinised using xylene, dehyd-
rated in a graded ethanol series and rinsed with 
distilled water. The staining procedure for EGFR was 
performed using EnVision FLEX, Dako. Proteinase K 
was used for antigen retrieval for 10 minutes at room 
temperature, followed by Peroxidase-Blocking 
Reagent for 10 minutes. Slides were incubated with 
Mouse Monoclonal Anti-Human EGFR Clone H11 
diluted 1:200 with buffer and incubated for an hour. 
Subsequently, HRP/FLEX was applied for an hour 
and visualization was achieved using chromogen 
diaminobenzidine diluted 2 drops in 1000ml substrate 
buffer for 30 seconds with hematoxylin serving as 
counterstain. Negative and positive controls were 
processed alongside each batch. 
Evaluation of EGFR expression 
All slides were evaluated independently by two 
pathologists who were unaware of the clinical 
diagnosis to each other’s evaluation. Any 
discrepancies arising between them were resolved 
using a conference microscope. To account for 
varying antigen expression within the tumour, 2-6 
different visual fields were observed at 20x and 40x. 
EGFR positivity was expressed as membranous 
and/or cytoplasmic brown colour deposition. Scoring 
for EGFR expression was as follows: negative (<10% 
positive-stained cells), mild (10-20% positive-stained 
cells), moderate (20-60% positive-stained cells) and 
strong (>60% positive-stained cells). 
Statistical Analysis 
Statistical analysis was performed using SPSS 
version 22 for Windows (SPSS Inc., Chicago, IL, USA). 
Cross-tabulations were run using chi-square test or 
Fisher’s exact test wherever necessary. Survival ana-
lysis was performed using the Kaplan-Meier and log- 
rank test. Any variables that were significant on the 
univariate analysis were further on multivariate. For 
all tests, p values <0.05 were considered significant. 
Results 
Premalignant patients  
The premalignant study population consisted of 
29 patients, 17 males (59%) and 12 females (41%) with 
a mean age of 43.45 (SD±20.56). Table 1 lists the 
characteristics of premalignant patients. EGFR 
expression was observed in 15 (52%) of cases. Mean 
age for EGFR negative and positive groups was 45.14 
(SD±19.34) and 41.87 (SD±22.20) respectively. EGFR 
overexpression had a significant correlation with site 
of lesion (p=0.041) as EGFR positive patients had 
upper/lower lip as most common lesion, whereas 
cheek was more common in the EGFR negative group. 
The majority of EGFR positive cases were mild 
positives with few moderate and no strong positives. 
OSCC patients  
The OSCC study population consisted of 100 
patients, with 56 males and 44 females having a mean 
age of 52.57 (SD±12.75). The most common primary 
site of lesion was the cheek, 65% followed by tongue, 
35%. Maximum cases of tongue were of the anterior, 
32% rather than posterior, 6%. Secondary sites 
included 27 cases of mandible, 12 of retromandible, 9 
of palate, 6 involving floor of the mouth and 1 of 
tonsil. Skin involvement was seen in 4 patients. The 
greater number of patients (56%) had moderately 
differentiated and AJCC stage II (30%) OSCC. After a 
follow up of 5 years, 44 of the total 100 patients had 
died and 65 had a recurrence of disease. EGFR 
overexpression was positive in 67 cases. Table 2 lists 
correlations of patient characteristics and EGFR 
status. EGFR was significantly associated with habits 
(p=0.039), recurrence (p=0.004) and also marginally 
with living status (p=0.053). EGFR expression was 
seen in 4/6 and 25/32 cases of posterior and anterior 
tongue respectively. 
 










EGFR Expression  
Chi Square /  
Fisher’s Exact Test 
 
 
p Value  
Positive (n=15, 51.7%)) Negative (n=14, 48.3%) 
N % N % N % 
Gender  Male 17 58.6 9 60.0 8 57.1 0.024 0.87 
  Female 12 41.4 6 40.0 6 42.9 










Cheek 7 24.1 2 13.3 5 35.7 
Gingiva 5 17.2 2 13.3 3 21.5 
Tongue 3 10.4 2 13.3 1 7.1 
Soft/Hard Palate 3 10.4 2 13.3 1 7.1 
Tonsil 1 3.4 0 0.0 1 7.1 




Hyperplastic Squamous Mucosa 3 10.3 2 13.3 1 7.1 
Extravasation Mucocele 4 13.8 3 20.0 1 7.1 
Retention Cyst 2 6.9 1 6.7 1 7.1 
Others 15 51.7 7 46.7 7 50.0 
EGFR Staining 
Score 
Mild 11 37.9       
Moderate 4 13.8 
Negative 14 48.3 
*Fishers’ exact test applied 








Figure 2. Kaplan-Meier disease free survival (left) and overall survival (right) curves in 100 OSCC patients selected according to EGFR status 













EGFR Expression  
Chi-square/ 




Positive (n=67) Negative (n=33)  
N / % N % N % 
Gender Male 56 37 55.2 19 57.6 0.05 0.824 
Female 44 30 44.8 14 42.4 
Age Division < 40 years 16 11 16.4 5 15.2 0.026 0.871 
≥40 years 84 56 83.6 28 84.8 
Histological Classification Well Differentiated 41 25 37.3 16 48.5 1.857* 0.379 
Moderately Differentiated 56 39 58.2 17 51.5 
Poorly Differentiated 3 3 4.5 0 0.0 
AJCC Stage I 18 9 13.4 9 27.3 7.067 0.07 
II 30 18 26.9 12 36.4 
III 27 23 34.3 4 12.1 
IV 25 17 25.4 8 24.2 
Habits Yes 73 46 68.7 27 81.8 6.23* 0.039** 
No 19 17 25.4 2 6.1 
Unknown 8 4 6.0 4 12.1 
Tobacco/ Smoking Yes 34 21 31.3 13 39.4 2.571 0.277 
No 41 26 38.8 15 45.5 
NA 25 20 29.9 5 15.2 
Paan/Supari Yes 57 34 50.7 23 69.7 3.526 0.172 
No 18 13 19.4 5 15.2 
NA 25 20 29.9 5 15.2 
Chalia/Gutka/Niswar Yes 27 16 23.9 11 33.3 2.76 0.277 
No 48 31 46.3 17 51.5 
NA 25 20 29.9 5 15.2 
Primary site Cheek 65 41 61.2 24 72.7 1.293 0.256 
Tongue 35 26 38.8 9 27.3 
Primary margins Clear 62 40 29.7 22 66.7 0.872* 0.708 
Near  30 22 32.8 8 24.2 
Involved 8 5 7.5 3 9.1 
Final T stage T1 21 11 16.4 10 30.3 5.1* 0.161 
T2 44 29 43.3 15 45.5 
T3 16 14 20.9 2 6.1 
T4 19 13 19.4 6 18.2 
Final N stage N0 75 48 71.6 27 81.8 2.2* 0.305 
N1 17 14 20.9 3 9.1 
N2 8 5 7.5 3 9.1 
Radiotherapy Yes 58 37 55.2 21 63.6 2.56* 0.299 
No 32 21 31.3 11 33.3 
Unknown 10 9 13.4 1 3.0 
5 year suvival Alive 56 33 49.3 23 69.7 3.75 0.053** 
Dead 44 34 50.4 10 30.3 
Recurrence Yes 65 50 74.6 15 45.5 8.271 0.004** 
No 35 17 25.4 18 54.5 




*Fishers’ exact test applied 
**p-value considered significant at <0.05 
AJCC: American Joint Commission on Cancer 
 
5 year survival and EGFR overexpression 
Living status was taken as the time interval from 
primary treatment until death or last follow-up taken 
at 5 years (60 months. Mean 5 year survival time for 
our population was 43 months with an overall 
survival rate of 56%. Univariate analysis showed that 
AJCC stage (p=0.004), final N stage (p=<0.001), EGFR 
expression (p=0.048) and EGFR staining intensity 
(p=0.015) all had a significant effect on 5 year survival. 
Moreover, EGFR expression (p=0.056) and AJCC 
stage (p=0.003) were also proven to be independent 
determiners of 5 year survival on the multivariate 
analysis (Table 3A and Table 3B). 
Disease free survival and EGFR overexpression 
Recurrence was defined as any relapse, 
locoregional or distant; however in our data there was 
no distant metastasis. Overall mean disease free 
survival time was 82 months with a recurrence rate of 
65%. Univariate analysis revealed AJCC stage (p=0.01, 
final N stage (p=<0.001), EGFR expression (p=0.01) 




and EGFR staining intensity (p=0.01) to be 
significantly associated with recurrence of patients. 
However, on the multivariate analysis only final N 
stage (p=<0.001) and EGFR expression (p=0.004) had 
a strong independent influence on disease free 
survival (Table 3A and Table 3B). 
Discussion 
Pakistan suffers from a very high prevalence of 
OSCC and the city of Karachi has been reported to 
have one of the highest incidences of OSCC 
worldwide [11, 36]. This is believed to be due, at least 
in part, to the widespread and persistent use of 
various risk factors, the most common ones being 
areca nut and betel quid [18]. Local data also supports 
this as paan, supari and chalia were the most 
frequently used substances in our patient population, 
which are all various cultural combinations of betel 
quid and areca nut, sometimes including tobacco. The 
5 year survival rate of OSCC ranges from 40-50% 
while the rate of recurrence is an alarming 50% within 
the first two years of diagnosis. 
An interesting role of EGFR may be in 
encouraging premalignant lesions towards maligna-
ncy. A majority of males and an average age of 55 
years was observed by Ries at al, in their 
premalignant population [21]. We report similar 
demographics with more male patients in our study 
and an average age of 45 years. Another study 
concerning only oral submucous fibrosis cases also on 
the Pakistani population reported a range of 18-54 
years and a majority of males [37]. The study group of 
Benchekroun et al. assessed EGFR expression in 162 
patients with oral premalignant lesions and found the 
female sex and a higher age to be significant factors 
for EGFR expression [22]. Moreover, our study 
showed that the upper/lower lip, as a site of lesion 
was an important factor in predicting EGFR 
overexpression. Carballeira et al. considered EGFR 
overexpression a bad prognostic criterion in lip 
squamous cell carcinoma patients as it had a marked 
effect on tumour ulceration and tumour thickness and 
width [38]. Although EGFR has been implicated in 
malignant transformation of premalignant lesions [22, 
23] exactly how it is overexpressed in terms of the 
mechanism of action needs further elucidation. This 
may be possible due to direct exposure to the sun as 
has been suggested by Yardimici et al. [39]. 
The OSCC patient population characteristics of 
our study were in alignment with previous studies 
from our population which also report the cheek as 
the most common site of lesion and moderately 
differentiated AJCC stage II as most frequent 
diagnosis for our population and wider geographical 
area [40] [41]. A mean age of 52 years and an almost 
equal incidence of both genders was found in our 
study which corroborated previous reports [42] [6].  
EGFR was overexpressed in the majority of our 
patients at 67%. Grandis et al. reported EGFR 
overexpression in 90% of HNSCC cases [43], while 
others report an average of 70-80% in oral and 
oropharnygeal cancers [44-46]. To the best of our 
knowledge, no studies regarding EGFR status in 
OSCC have been performed on our population, thus a 
parallel cannot be drawn. The Indian population can 
be considered geographically, genetically and 
habitually close to ours. EGFR positivity was reported 
in 27.5% and 72.5% of OSCC cases as low and high 
expression respectively, by Gupta et al. which 
corroborates our findings [33]. Another study 
concluded a median overexpression of 50% [46]. 
However, Khan et al reported an outstanding 92.8% 
positivity for EGFR which is well above our findings 
[47]. Considering site-specific expression, EGFR 
overexpression was seen in cheek (46%) more than the 
tongue (24%). This may be correlated with the 
chewing habits of our population since it is a common 
practice to stuff paan/supari between the gingiva and 
cheek which allows maximum penetration and 
absorption, and this was also the most commonly 
used substance of our data set. 
The majority of people who were involved in at 
least one kind of habit were confirmed EGFR positive 
(67%) and this was statistically significant (p=0.039), 
which leads to the possibility that these substances 
maybe acting on the EGFR gene and causing 
mutations which result in overexpression of the 
receptor. This has been demonstrated by previous 
studies in which EGFR was identified as one of the 
most commonly mutated genes due to exposure to 
risk factors in OSCC [19]. Previous accounts on our 
population have reported associations between oral 
cavity cancer incidences and the use of these, 
although EGFR has not been implicated as an agent of 
carcinogenesis before [12] [18]. 
Patient 5 year survival is the gold standard by 
which the viability of any prognostic biomarker is 
evaluated. The majority of our patients were living 
(57%) at the end of follow up and recurrence was 
observed in 65% of the total. Authors also report a 
5-year survival rate of 40-50% [48] with 50% of 
patients developing recurrence within the first two 
years of treatment [4]. We determined that EGFR 
significantly and independently affected 5 year 
survival and recurrence, with EGFR positive patients 
having markedly lower survival rates and increased 
chances of recurrence. 




Table 3A. Overall survival and recurrence at 5 years (univariate analysis) 
Factor Group 5 year survival Disease Free Survival 
N Months P-value N Months P-value 
Gender Male 56 42.37 0.719 56 62.85 0.59 
Female 44 42.81 44 88.94 
Age Division < 40 years 16 40.25 0.609 16 67.15 0.95 
≥40 years 84 43.01 84 81.39 
Histological Classification Well Differentiated 41 46.41 0.136 41 112.02 0.14 
Moderately Differentiated 56 40.50 56 52.64 
Poorly Differentiated 3 28.66 3 41.33 
AJCC Stage I 18 49.66 0.004* 18 72.47 0.01* 
II 30 49.70 30 123.63 
III 27 42.11 27 47.32 
IV 25 29.40 25 40.75 
Habits Yes 73 42.98 0.879 73 63.34 0.26 
No 19 40.10 19 75.27 
Unknown 8 44.62 8 104.50 
Primary site Cheek 65 41.04 0.338 65 62.28 0.38 
Tongue 35 45.40 35 93.99 
Primary margins Clear 62 45.27 0.187 62 81.75 0.85 
Near  30 40.46 30 61.68 
Involved 8 29.50 8 59.56 
Final T stage T1 21 49.52 0.075 21 65.47 0.258 
T2 44 43.72 44 101.94 
T3 16 43.93 16 50.64 
T4 19 31.05 19 44.42 
Final N stage N0 75 47.40 <0.001* 75 98.52 <0.001* 
N1 17 30.88 17 28.04 
N2 8 22.12 8 11.25 
Radiotherapy Yes 58 39.82 0.223 58 51.14 0.16 
No 32 46.25 32 98.52 
Unknown 10 46.70 10 93.06 
EGFR expression Positive 67 39.28 0.048* 67 56.82 0.01* 
Negative 33 49.24 33 99.10 




Mild 11 47.81 11 82.03 
Moderate 41 34.41 41 41.42 
Strong 15 46.33 15 44.73 
 
Table 3B. Overall survival and recurrence at 5 years (multivariate analysis) 
Factor Group 5 year survival Disease free survival 
N Exp (β) P - value 95% CI of Exp (β) N Exp (β) P - value 95% CI of Exp (β 
Final N stage N0 ** ** ** ** 75 1 <0.001*  
 N1 17 2.373 1.27-4.41 
 N2 8 5.382 2.28-12.66 
EGFR expression Positive 67 2.024 0.056* 0.983-4.165 67 2.39 0.004* 1.32-4.31 
 Negative 33 1.00 33 1.00 
AJCC Stage I 18  0.003*  † † † † 
 II 30 0.977 0.327-2.92 
 III 27 1.606 0.564-4.573 
 IV 25 3.705 1.359-10.09 
*p-value considered significant at <0.05 
**Final N stage was not significant for living status 
†AJCC stage was not significant for recurrence 
 
This provides compelling evidence for the use of 
EGFR as a prognostic tool since it was as strong a 
predictor of survival and recurrence as AJCC staging 
and nodal metastasis. In accordance with our study, 
Gupta et. al also showed that EGFR overexpression 
was significantly related to recurrence and added that 
it also meant an early time to recurrence [4]. 
Moreover, an improved disease-free interval has been 
observed with low levels of EGFR accompanied by 
chemoradiation [33]. Another study using tissue 
microarray technology also concluded that EGFR 
overexpression (cytoplasmic and membranous both) 
had a negative prognostic influence as overall and 
disease-free survival both were lowered [49]. 
The use of EGFR in targeted anticancer therapy 
is showing differing yet promising results in OSCC. A 




study based on functional genomics has clarified that 
certain mutations are more responsive towards 
targeted therapy, highlighting the importance of 
knowing the exact mutations in our patients before 
we begin their therapy [50]. 
Regarding premalignant lesion transition to 
malignancy, our data could not conclude a significant 
role for EGFR, possibly due to the low sample size 
and technique involved. For OSCC however, EGFR 
was proved a reliable biomarker for predicting the 
overall survival and disease free survival of patients, 
with as much of an independent impact as AJCC 
staging and lymph node involvement, and it may be 
used to identify high-risk subgroups in our 
population and guide their subsequent therapy. 
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